ALAR
Alarum Technologies Ltd.
Software - Infrastructure
Market Cap$58M
5Y Perf.+37.8%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ALAR vs BCYC vs CGNT vs PEPG
Revenue, margins, valuation, and 5-year total return — side by side.
BCYC
Bicycle Therapeutics plc
Biotechnology
Market Cap$339M
5Y Perf.-69.4%
CGNT
Cognyte Software Ltd.
Software - Infrastructure
Market Cap$793M
5Y Perf.+55.4%
PEPG
PepGen Inc.
Biotechnology
Market Cap$123M
5Y Perf.-84.0%
ALAR vs BCYC vs CGNT vs PEPG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ALAR | BCYC | CGNT | PEPG |
|---|---|---|---|---|
| Industry | Software - Infrastructure | Biotechnology | Software - Infrastructure | Biotechnology |
| Market Cap | $58M | $339M | $793M | $123M |
| Revenue (TTM) | $36M | $63M | $377M | $0.00 |
| Net Income (TTM) | $1M | $-219M | $-5M | $-90M |
| Gross Margin | 62.8% | -13.3% | 70.9% | — |
| Operating Margin | 1.6% | -381.6% | 0.9% | — |
| Forward P/E | 9.4x | — | 46.9x | — |
| Total Debt | $2M | $18M | $36M | $17M |
| Cash & Equiv. | $15M | $628M | $113M | $61M |
ALAR vs BCYC vs CGNT vs PEPG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ALAR
BCYC
CGNT
PEPG
| Stock | May 22 | May 26 | Return |
|---|---|---|---|
| Alarum Technologies… (ALAR) | 100 | 137.8 | +37.8% |
| Bicycle Therapeutic… (BCYC) | 100 | 30.6 | -69.4% |
| Cognyte Software Lt… (CGNT) | 100 | 155.4 | +55.4% |
| PepGen Inc. (PEPG) | 100 | 16.0 | -84.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALAR vs BCYC vs CGNT vs PEPG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALAR leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. PepGen Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. BCYC also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ALAR
Alarum Technologies Ltd.
The Income Pick
ALAR carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 2 yrs, beta 2.01
- Better valuation composite
- 3.3% margin vs BCYC's -345.0%
- 3.2% ROA vs PEPG's -60.4%, ROIC 59.0% vs -73.2%
Best for: income & stability
BCYC
Bicycle Therapeutics plc
The Growth Play
BCYC is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 105.8%, EPS growth -9.0%, 3Y rev CAGR 71.2%
- -59.3% 10Y total return vs CGNT's -60.7%
- 105.8% revenue growth vs PEPG's -1.0%
Best for: growth exposure and long-term compounding
CGNT
Cognyte Software Ltd.
The Secondary Option
CGNT lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: technology exposure
PEPG
PepGen Inc.
The Defensive Pick
PEPG is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.17, Low D/E 11.5%, current ratio 11.94x
- Beta 0.17, current ratio 11.94x
- Beta 0.17 vs ALAR's 2.01
- +42.1% vs BCYC's -37.1%
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BCYC | 105.8% revenue growth vs PEPG's -1.0% |
| Value | ALAR | Better valuation composite |
| Quality / Margins | ALAR | 3.3% margin vs BCYC's -345.0% |
| Stability / Safety | PEPG | Beta 0.17 vs ALAR's 2.01 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PEPG | +42.1% vs BCYC's -37.1% |
| Efficiency (ROA) | ALAR | 3.2% ROA vs PEPG's -60.4%, ROIC 59.0% vs -73.2% |
ALAR vs BCYC vs CGNT vs PEPG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
Segment breakdown not available.
ALAR vs BCYC vs CGNT vs PEPG — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLALARLAGGINGPEPG
Who Leads Where
ALAR leads in 5 of 6 categories
BCYC leads 0 • CGNT leads 0 • PEPG leads 0 • 1 tied
Explore the data ↓PEPGPepGen Inc.
0leads
CGNTCognyte Software Ltd.
0leads
BCYCBicycle Therapeutics …
0leads
ALARAlarum Technologies L…
5leads
6 Total Categories
CATEGORYLEADERvs BCYCvs CGNTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALAR4/6
Valuation MetricsMultiples, price ratios, and targets
ALAR3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALAR6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ALAR3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
ALAR1/1
Income & Cash Flow (Last 12 Months)
ALAR leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CGNT and PEPG operate at a comparable scale, with $377M and $0 in trailing revenue. ALAR is the more profitable business, keeping 3.3% of every revenue dollar as net income compared to BCYC's -3.4%. On growth, ALAR holds the edge at +80.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ALARAlarum Technologi… | BCYCBicycle Therapeut… | CGNTCognyte Software … | PEPGPepGen Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $36M | $63M | $377M | $0 |
| EBITDAEarnings before interest/tax | $1M | -$238M | $16M | -$90M |
| Net IncomeAfter-tax profit | $1M | -$219M | -$5M | -$90M |
| Free Cash FlowCash after capex | $0 | -$229M | $11M | -$82M |
| Gross MarginGross profit ÷ Revenue | +62.8% | -13.3% | +70.9% | — |
| Operating MarginEBIT ÷ Revenue | +1.6% | -3.8% | +0.9% | — |
| Net MarginNet income ÷ Revenue | +3.3% | -3.4% | -1.2% | — |
| FCF MarginFCF ÷ Revenue | +27.5% | -3.6% | +3.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +80.3% | -91.1% | +15.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -99.0% | +1.1% | +173.6% | +60.3% |
ALAR leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
ALAR leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, ALAR's 5.8x EV/EBITDA is more attractive than CGNT's 83.9x.
| Metric | ALARAlarum Technologi… | BCYCBicycle Therapeut… | CGNTCognyte Software … | PEPGPepGen Inc. |
|---|---|---|---|---|
| Market CapShares × price | $58M | $339M | $793M | $123M |
| Enterprise ValueMkt cap + debt − cash | $44M | -$272M | $715M | $80M |
| Trailing P/EPrice ÷ TTM EPS | 9.40x | -1.55x | -64.71x | -0.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 46.93x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 5.82x | — | 83.91x | — |
| Price / SalesMarket cap ÷ Revenue | 1.81x | 4.67x | 2.26x | — |
| Price / BookPrice ÷ Book value/share | 2.07x | 0.56x | 3.64x | 0.51x |
| Price / FCFMarket cap ÷ FCF | 6.58x | — | 23.59x | — |
ALAR leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
ALAR leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ALAR delivers a 4.2% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-76 for PEPG. BCYC carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGNT's 0.16x. On the Piotroski fundamental quality scale (0–9), ALAR scores 6/9 vs BCYC's 2/9, reflecting solid financial health.
| Metric | ALARAlarum Technologi… | BCYCBicycle Therapeut… | CGNTCognyte Software … | PEPGPepGen Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +4.2% | -35.7% | -2.0% | -75.7% |
| ROA (TTM)Return on assets | +3.2% | -29.5% | -0.9% | -60.4% |
| ROICReturn on invested capital | +59.0% | — | -2.5% | -73.2% |
| ROCEReturn on capital employed | +32.8% | -32.0% | -1.8% | -63.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 2 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.06x | 0.03x | 0.16x | 0.12x |
| Net DebtTotal debt minus cash | -$13M | -$611M | -$77M | -$44M |
| Cash & Equiv.Liquid assets | $15M | $628M | $113M | $61M |
| Total DebtShort + long-term debt | $2M | $18M | $36M | $17M |
| Interest CoverageEBIT ÷ Interest expense | 17.18x | -1465.53x | 21.71x | — |
ALAR leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ALAR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALAR five years ago would be worth $6,341 today (with dividends reinvested), compared to $1,389 for PEPG. Over the past 12 months, PEPG leads with a +42.1% total return vs BCYC's -37.1%. The 3-year compound annual growth rate (CAGR) favors ALAR at 60.6% vs PEPG's -50.7% — a key indicator of consistent wealth creation.
| Metric | ALARAlarum Technologi… | BCYCBicycle Therapeut… | CGNTCognyte Software … | PEPGPepGen Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.6% | -26.8% | +23.6% | -75.0% |
| 1-Year ReturnPast 12 months | +20.5% | -37.1% | +13.4% | +42.1% |
| 3-Year ReturnCumulative with dividends | +314.0% | -77.4% | +155.8% | -88.1% |
| 5-Year ReturnCumulative with dividends | -36.6% | -84.6% | -54.7% | -86.1% |
| 10-Year ReturnCumulative with dividends | -99.6% | -59.3% | -60.7% | -86.1% |
| CAGR (3Y)Annualised 3-year return | +60.6% | -39.1% | +36.8% | -50.7% |
ALAR leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CGNT and PEPG each lead in 1 of 2 comparable metrics.
Risk & Volatility
PEPG is the less volatile stock with a 0.17 beta — it tends to amplify market swings less than ALAR's 2.01 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CGNT currently trades 94.3% from its 52-week high vs PEPG's 22.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ALARAlarum Technologi… | BCYCBicycle Therapeut… | CGNTCognyte Software … | PEPGPepGen Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.01x | 1.65x | 1.27x | 0.17x |
| 52-Week HighHighest price in past year | $18.00 | $9.36 | $11.66 | $7.80 |
| 52-Week LowLowest price in past year | $5.50 | $4.24 | $6.29 | $1.01 |
| % of 52W HighCurrent price vs 52-week peak | +44.4% | +52.2% | +94.3% | +22.9% |
| RSI (14)Momentum oscillator 0–100 | 65.3 | 57.0 | 66.7 | 37.6 |
| Avg Volume (50D)Average daily shares traded | 37K | 464K | 496K | 1.5M |
Evenly matched — CGNT and PEPG each lead in 1 of 2 comparable metrics.
Analyst Outlook
ALAR leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: BCYC as "Buy", CGNT as "Hold", PEPG as "Buy". Consensus price targets imply 291.1% upside for PEPG (target: $7) vs -2.3% for CGNT (target: $11).
| Metric | ALARAlarum Technologi… | BCYCBicycle Therapeut… | CGNTCognyte Software … | PEPGPepGen Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $10.67 | $10.75 | $7.00 |
| # AnalystsCovering analysts | — | 21 | 5 | 6 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 2 | — | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.7% | 0.0% |
ALAR leads this category, winning 1 of 1 comparable metric.
Key Takeaway
ALAR leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallAlarum Technologies Ltd. (ALAR)Leads 5 of 6 categories
Loading custom metrics...
ALAR vs BCYC vs CGNT vs PEPG: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ALAR or BCYC or CGNT or PEPG a better buy right now?
For growth investors, Bicycle Therapeutics plc (BCYC) is the stronger pick with 105.
8% revenue growth year-over-year, versus 11. 9% for Cognyte Software Ltd. (CGNT). Alarum Technologies Ltd. (ALAR) offers the better valuation at 9. 4x trailing P/E, making it the more compelling value choice. Analysts rate Bicycle Therapeutics plc (BCYC) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ALAR or BCYC or CGNT or PEPG?
Over the past 5 years, Alarum Technologies Ltd.
(ALAR) delivered a total return of -36. 6%, compared to -86. 1% for PepGen Inc. (PEPG). Over 10 years, the gap is even starker: BCYC returned -59. 3% versus ALAR's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ALAR or BCYC or CGNT or PEPG?
By beta (market sensitivity over 5 years), PepGen Inc.
(PEPG) is the lower-risk stock at 0. 17β versus Alarum Technologies Ltd. 's 2. 01β — meaning ALAR is approximately 1062% more volatile than PEPG relative to the S&P 500. On balance sheet safety, Bicycle Therapeutics plc (BCYC) carries a lower debt/equity ratio of 3% versus 16% for Cognyte Software Ltd. — giving it more financial flexibility in a downturn.
04Which is growing faster — ALAR or BCYC or CGNT or PEPG?
By revenue growth (latest reported year), Bicycle Therapeutics plc (BCYC) is pulling ahead at 105.
8% versus 11. 9% for Cognyte Software Ltd. (CGNT). On earnings-per-share growth, the picture is similar: Alarum Technologies Ltd. grew EPS 160. 7% year-over-year, compared to -9. 0% for Bicycle Therapeutics plc. Over a 3-year CAGR, BCYC leads at 71. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ALAR or BCYC or CGNT or PEPG?
Alarum Technologies Ltd.
(ALAR) is the more profitable company, earning 18. 2% net margin versus -301. 7% for Bicycle Therapeutics plc — meaning it keeps 18. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALAR leads at 21. 1% versus -341. 3% for BCYC. At the gross margin level — before operating expenses — BCYC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ALAR or BCYC or CGNT or PEPG more undervalued right now?
Analyst consensus price targets imply the most upside for PEPG: 291.
1% to $7. 00.
07Which pays a better dividend — ALAR or BCYC or CGNT or PEPG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ALAR or BCYC or CGNT or PEPG better for a retirement portfolio?
For long-horizon retirement investors, PepGen Inc.
(PEPG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 17)). Alarum Technologies Ltd. (ALAR) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PEPG: -86. 1%, ALAR: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ALAR and BCYC and CGNT and PEPG?
These companies operate in different sectors (ALAR (Technology) and BCYC (Healthcare) and CGNT (Technology) and PEPG (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ALAR is a small-cap high-growth stock; BCYC is a small-cap high-growth stock; CGNT is a small-cap quality compounder stock; PEPG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ALAR: 80.3% · BCYC: -91.1%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.